{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE303nnn/GSE303076/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303076"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Super-enhancer-driven ELF3/JUNB promotes prostate cancer resistance to abiraterone by regulating WNT11","description":"Super Enhancers (SEs) play a key role in castration-resistant prostate cancer (CRPC) drug resistance. By integrating ChIP-seq and RNA-seq analyses, we identified aberrantly activated super enhancers at the ELF3 and JUNB loci driving their transcriptional up-regulation in abiraterone-resistant prostate cancer cells. Mechanistically, ELF3/JUNB complex directly interacted and activated WNT11 to promote drug resistance and neuroendocrine transformation of prostate cancer cells. In vitro and in vivo experiments confirmed that targeting ELF3/JUNB significantly restored abiraterone sensitivity. This study reveals a critical role of the SE-driven ELF3/JUNB-WNT11 axis in CRPC resistance, providing a new potential therapeutic target to overcome abiraterone resistance.","dates":{"publication":"2026/09/03"},"accession":"GSE303076","cross_references":{"GSM":["GSM9117279","GSM9117278","GSM9117286","GSM9117285","GSM9117287","GSM9117282","GSM9117281","GSM9117284","GSM9117283","GSM9117280"],"GPL":["29480"],"GSE":["303076"],"taxon":["Homo sapiens"],"PMID":["[42527507]"]}}